Saturn V Capital Management’s iTeos Therapeutics ITOS Stock Holding History

Saturn V Capital Management’s Portfolio ITOS Stock Details ITOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-195,704	Closed	-$2M	–	26
2024 Q3	$2M	Sell	195,704 -171,725	-47%	-$2.62M	0.71%	22
2024 Q2	$5.45M	Sell	367,429 -19,666	-5%	-$282K	2.06%	19
2024 Q1	$5.28M	Sell	387,095 -441,137	-53%	-$4.81M	2.12%	17
2023 Q4	$9.07M	Sell	828,232 -166,524	-17%	-$1.65M	3.47%	12
2023 Q3	$10.9M	Buy	994,756 +358,598	+56%	+$4.59M	4.56%	11
2023 Q2	$8.42M	Buy	636,158 +155,505	+32%	+$2.22M	4.67%	11
2023 Q1	$6.54M	Buy	480,653 +138,582	+41%	+$2.48M	4.89%	12
2022 Q4	$7.03M	Buy	+342,071	New	+$6.68M	5.83%	8

Other funds holding ITOS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Saturn V Capital Management's ITOS Position: Q4 2024 in Review

Saturn V Capital Management sold out of iTeos Therapeutics (ITOS) in Q4 2024, closing a stake of 195,704 shares — an estimated $2M sold.

Saturn V Capital Management first reported a position in ITOS in Q4 2022 and held it in 8 quarters. The position peaked at $10.9M in Q3 2023. 136 funds tracked by Wall St. Rank hold ITOS as of Q4 2024.

Saturn V Capital Management reported no remaining iTeos Therapeutics position as of Q4 2024 after selling out during the quarter.
Saturn V Capital Management sold 195,704 iTeos Therapeutics shares in Q4 2024, an estimated $2M.
Saturn V Capital Management first reported a position in iTeos Therapeutics in Q4 2022 and held it in 8 quarters.
Saturn V Capital Management's iTeos Therapeutics position peaked at $10.9M in Q3 2023.
136 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q4 2024.

Based on Saturn V Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.